Education
About Us
Working with TipRanks
Follow Us
iX Biopharma Ltd. (SG:42C)
:42C
Total Valuation
iX Biopharma Ltd. has a market cap or net worth of S$103.99M. The enterprise value is S$19.22M.
Market CapS$103.99M
Enterprise ValueS$19.22M
Share Statistics
iX Biopharma Ltd. has 888,843,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding888,843,400
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
iX Biopharma Ltd.’s return on equity (ROE) is -27.78 and return on invested capital (ROIC) is -94.36%.
Return on Equity (ROE)-27.78
Return on Assets (ROA)-0.90
Return on Invested Capital (ROIC)-94.36%
Return on Capital Employed (ROCE)-2.73
Revenue Per Employee221.91K
Profits Per Employee-289.74K
Employee Count35
Asset Turnover0.69
Inventory Turnover6.21
Valuation Ratios
The current PE Ratio of iX Biopharma Ltd. is ―. iX Biopharma Ltd.’s PEG ratio is 0.08.
PE Ratio―
PS Ratio1.80
PB Ratio38.32
Price to Fair Value38.32
Price to FCF-3.53
Price to Operating Cash Flow-27.68
PEG Ratio0.08
Income Statement
In the last 12 months, iX Biopharma Ltd. had revenue of 7.77M and earned -10.14M in profits. Earnings per share was -0.01.
Revenue7.77M
Gross Profit2.04M
Operating Income-6.29M
Pretax Income-10.14M
Net Income-10.14M
EBITDA-8.96M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -3.76M and capital expenditures -201.00K, giving a free cash flow of -3.96M billion.
Operating Cash Flow-3.76M
Free Cash Flow-3.96M
Free Cash Flow per Share>-0.01
Dividends & Yields
iX Biopharma Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.06
52-Week Price Change500.00%
50-Day Moving Average0.05
200-Day Moving Average0.03
Relative Strength Index (RSI)76.92
Average Volume (3m)19.06M
Important Dates
iX Biopharma Ltd. upcoming earnings date is Feb 6, 2026, TBA (Confirmed).
Last Earnings DateAug 29, 2025
Next Earnings DateFeb 6, 2026
Ex-Dividend Date―
Financial Position
iX Biopharma Ltd. as a current ratio of 0.47, with Debt / Equity ratio of 1616.99%
Current Ratio0.47
Quick Ratio0.37
Debt to Market Cap0.40
Net Debt to EBITDA-0.56
Interest Coverage Ratio-19.58
Taxes
In the past 12 months, iX Biopharma Ltd. has paid 1.00K in taxes.
Income Tax1.00K
Effective Tax Rate>-0.01
Enterprise Valuation
iX Biopharma Ltd. EV to EBITDA ratio is -2.12, with an EV/FCF ratio of -4.81.
EV to Sales2.45
EV to EBITDA-2.12
EV to Free Cash Flow-4.81
EV to Operating Cash Flow-5.06
Balance Sheet
iX Biopharma Ltd. has S$866.00K in cash and marketable securities with S$5.90M in debt, giving a net cash position of -S$5.04M billion.
Cash & Marketable SecuritiesS$866.00K
Total DebtS$5.90M
Net Cash-S$5.04M
Net Cash Per Share>-S$0.01
Tangible Book Value Per Share<S$0.01
Margins
Gross margin is 26.26%, with operating margin of -80.92%, and net profit margin of -130.57%.
Gross Margin26.26%
Operating Margin-80.92%
Pretax Margin-130.55%
Net Profit Margin-130.57%
EBITDA Margin-115.42%
EBIT Margin-126.42%
Analyst Forecast
The average price target for iX Biopharma Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast30.34%
EPS Growth Forecast17.14%